Zymeworks
Market cap $1.78B 69.0M shares (10-Q, Nov 6, 2026) × $25.84 close Nov 17, 2026
Most recent annual filing: 2026-03-02
- Zanidatamab NMPA China decision2026Zanidatamab NMPA China decision, 2026, major
- ZW191 interim2026ZW191 interim, 2026, notable
- ZW1528 IND filing2026ZW1528 IND filing, 2026, notable
- YUPELRI/TRELEGY ELLIPTA milestone corporate update1Q 2027YUPELRI/TRELEGY ELLIPTA milestone corporate update, 1Q 2027, routine
- TRELEGY ELLIPTA corporate update1Q 2027TRELEGY ELLIPTA corporate update, 1Q 2027, routine
- Trelegy Ellipta milestone corporate update1Q 2027Trelegy Ellipta milestone corporate update, 1Q 2027, routine
- R&D Day corporate updateFeb 11, 2027R&D Day corporate update, Feb 11, 2027, routine
- Pasritamig J&J Ph3 startDec 2027Pasritamig J&J Ph3 start, Dec 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
pasritamig
JNJ-78278343ZW191
ZW251
ZW220
ZW209
ZW1528
YUPELRI
revefenacinTechnology platforms
Azymetric
Multispecific antibody platform enabling bispecific and trispecific antibody development with dual-targeting of receptors/ligands; foundation for ADCs and MSATs in oncology, inflammation, and autoimmune disease; partnered with GSK, Daiichi Sankyo, J&J, and Merck
Targets: HER2
EFECT
Antibody effector function modulation platform consisting of Fc region modifications enabling selective enhancement or suppression of immune effector function; used in oncology, inflammation, and autoimmune therapeutics
ProTECT
Conditionally active antibody technology that masks an antibody arm outside the tumor to minimize off-target effects; activates in tumor microenvironment via protease cleavage; designed to improve therapeutic window in oncology
Pan-RAS ADC
Proprietary Pan-RAS antibody-drug conjugate (ADC) platform; company evaluating formation of a separate dedicated entity with third-party capital to advance multiple product candidates into clinical studies.
Targets: RAS
TriTCE Co-Stim
Trispecific T cell engager co-stimulation platform used to configure T cell engagers targeting tumor antigens with simultaneous CD3 and CD28 engagement; focus on solid tumors and DLL3-expressing cancers
Targets: DLL3, CD3, CD28
Drug Conjugate Platforms
Suite of proprietary cytotoxins (topoisomerase and microtubulin inhibiting toxins), stable linkers, and conjugation technologies for ADC development in oncology; includes novel TOPO1i payload ZD06519
Discontinued (1)
- ZW171 — undisclosed · discontinued in 2025
Capital (as filed)
- Cash
- $100M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$24.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $573M cash per the update of Aug 25, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-17 UPDATE: Zymeworks (ZYME) - The Milestones Become Buybacks 🔒 Paid
- 2026-11-10 UPDATE: Zymeworks (ZYME) - The Royalty Line Prints 🔒 Paid
- 2026-10-27 UPDATE: Zymeworks (ZYME) - ZW191 Survives Contact ★ Distilled Pro
- 2026-10-24 UPDATE: Zymeworks (ZYME) - Roche Buys the Trispecific 🔒 Paid
- 2026-09-24 UPDATE: Zymeworks (ZYME) - Theravance Is In the Building 🔒 Paid
- 2026-08-25 UPDATE: Zymeworks (ZYME) - The Flywheel Caught 🔒 Paid
- 2026-08-07 UPDATE: Zymeworks (ZYME) - The Runway Guidance Just Disappeared 🔒 Paid
- 2026-07-09 Zymeworks Inc. (ZYME) — Scientific Deep Dive for Zanidatamab (Ziihera®), ZW191, and the Royalty-Aggregation Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Zymeworks, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-09 Watch Zymeworks Inc. (ZYME) — Scientific Deep Dive for Zanidatamab (Ziihera®), ZW191, and the Royalty-Aggregation Pipeline Zanidatamab is approved and milestone-rich but the royalty-aggregation model is unproven and the balance sheet is heavily leveraged; wait for the Aug 25 PDUFA to confirm the flywheel.
- 2026-08-07 Speculative buy speculative UPDATE: Zymeworks (ZYME) - The Runway Guidance Just Disappeared Stock is 13% lower than a month ago, below management's own buyback price, going into a well-telegraphed approval that unlocks $250M, but withdrawn runway guidance and $77.7M Q2 cash burn keep conviction speculative.
- 2026-08-25 Buy core UPDATE: Zymeworks (ZYME) - The Flywheel Caught FDA approved zanidatamab with a broader-than-expected label (IHC 2+/ISH+, no PD-L1 gate), the $250M milestone is earned, and the argument shifts from 'a milestone is coming' to 'the franchise is bigger than modeled.'
- 2026-09-24 Buy core UPDATE: Zymeworks (ZYME) - Theravance Is In the Building Theravance acquisition closed, removing the last named execution risk; the OMERS financing keeps the parent balance sheet out of lenders' reach and is sized to be repaid before YUPELRI generics arrive.
- 2026-10-24 Buy core UPDATE: Zymeworks (ZYME) - Roche Buys the Trispecific Roche's $55M upfront for ZW209 validates the out-licensing model and delivers $95M of near-term non-dilutive cash, but the core royalty ramp thesis is unchanged.
- 2026-10-27 Buy core UPDATE: Zymeworks (ZYME) - ZW191 Survives Contact Randomized ZW191 data (n=80) confirmed a 64.5% response rate at the lower dose with half the severe toxicity, giving the banker a stronger package to sell, but value only materializes through a deal not yet signed.
- 2026-11-10 Buy core UPDATE: Zymeworks (ZYME) - The Royalty Line Prints Mature OS data (HR 0.65) largely removes clinical risk on the GEA franchise, royalties grew to $2.3M in the first partial quarter of the new label, and insiders bought ~$66M near $28, but recurring revenue still doesn't cover the business.
- 2026-11-17 Buy core UPDATE: Zymeworks (ZYME) - The Milestones Become Buybacks A new $200M buyback funded by the Roche and Trelegy milestones signals management confidence after a 14.8% drawdown, but recurring cash still doesn't cover the business and the program depends on two milestones not yet received.
- Long call · opened Aug 7, 2026 at $23.54 · +9.8% vs XBI -7.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In April 2026, the U.S. Food and Drug Administration ("FDA") accepted the sBLA filing for Ziihera® (zanidatamab-hrii) combinations for the first-line treatment of adult patients with HER2+ unresectable locally advanced or metastatic gastric, gastroesophageal junction ("GEJ"), or GEA for priority review with a PDUFA date of August 25, 2026.”
matched to Zanidatamab (China NMPA) · regulatory decision / matched to Zanidatamab (HERIZON-GEA-01) · interim data
-
-
-
“Table of Contents Partnered Programs Zanidatamab The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026.”
matched to Zanidatamab (HERIZON-GEA-01) · interim data · since happened Aug 31, 2026 -
“The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026.”
matched to Zanidatamab (HERIZON-GEA-01) · interim data · since happened Aug 31, 2026
-
-
-
“The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026.”
matched to Zanidatamab (HERIZON-GEA-01) · interim data · since happened Aug 31, 2026
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (31)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseZymeworks Announces $200 Million Share Repurchase Authorization Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibil→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateWith the stock down 14% from last week's close, Zymeworks just authorized a new $200M buyback — bigger than the entire program it just completed — signaling management believes their own paper is cheap and answering the specific question I flagged after Q3 earnings.
- Nov 9, 2026ReleaseZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 mi→ BD updateSummary on the 8-K
- Nov 9, 20268-K/ACurrent report (amended) · EX-99.3→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateQ3 earnings landed after the close with a guidance raise, the HERIZON-GEA-01 final OS readout (median 27 months, HR 0.65 with the triplet), and pasritamig Phase 1 combination data showing a 73% PSA50 response — the flywheel is accelerating on multiple fronts simultaneously.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 27, 2026ReleaseFaeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directorsvia aggregator
- Oct 26, 2026DEFA14AProxy soliciting material
- Oct 26, 2026DEF 14AProxy statement
- Oct 24, 2026ReleaseZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026via aggregator→ BD updateThe randomized Part 2a dose-optimization data I've been waiting for just landed at ESMO: ZW191 hit 64.5% confirmed ORR in high-grade serous PROC at 6.4 mg/kg with a 100% disease control rate, median duration of response not reached at 7 months, and a dramatically cleaner safety profile than the higher dose — and the FRα-negative activity that makes this drug different from Elahere held up in the randomized cohort.
- Oct 23, 2026ReleaseZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3via aggregator→ BD updateSummary on the 8-K
- Oct 23, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1→ BD updateZymeworks just signed a global Roche partnership for ZW209 — the DLL3 trispecific T-cell engager I called a placeholder — for $55M upfront, $40M at Phase 1b, and up to $718M in milestones. The R&D-to-royalty engine just printed its first wholly-owned deal.BD extracted 2 program updates from this document → ZYME pipeline
- Oct 19, 2026ReleaseZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharmavia aggregator
- Oct 15, 2026ReleaseZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Resultsvia aggregator
- Sep 28, 2026ReleaseZymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisitionvia aggregator
- Sep 23, 2026ReleaseZymeworks Completes Acquisition of Theravance Biopharma Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWI→ BD updateSummary on the 8-K
- Sep 23, 20268-KCurrent report: material agreement, acquisition / disposition, debt / obligation · EX-99.1→ BD updateThe Theravance deal closed today, adding ~$360M of target cash and ~$60M/yr of YUPELRI profit-share to the balance sheet — and the $350M OMERS note terms are now fully in print, revealing an 8.25% fixed rate and a waterfall that directs 75% of YUPELRI Adjusted Net Profit to debt service.
- Aug 25, 2026ReleaseU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinomavia aggregator→ BD updateSummary on the 8-KBD extracted 1 program update from this document → ZYME pipeline
- Aug 25, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe flywheel just caught: FDA approved two Ziihera+chemo regimens in 1L HER2+ GEA on the August 25 PDUFA date, triggering the $250M Jazz milestone that transforms the balance sheet and de-risks the royalty-aggregation thesis in one wire transfer.
- Aug 11, 2026ReleaseZymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a port
- Aug 6, 2026ReleaseZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsvia aggregator
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → ZYME pipeline
- Aug 6, 202610-QQuarterly report
- Jun 29, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- May 14, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 7, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 1, 20268-KCurrent report: officer / director change · EX-99.1
- Mar 2, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Mar 2, 20268-KCurrent report: material agreement, debt / obligation, Reg FD disclosure · EX-99.1
- Mar 2, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 26, 2026ARSAnnual report to shareholders
- Oct 16, 2026PRE 14APRE 14A
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 2, 2026S-8Employee plan registration